Investor Presentaiton

E Kwality: Key Highlights B Development capabilities in complex products: Specialist capabilities, expertise, and know-how in Long-chain acting injectables, Liposomal injectables, Lipid nano particles/Lipid complexes, Lyophilized injectables, Protein-based injectables, and complex ophthalmic Highly experienced leadership team: The management team at Kwality has extensive experience in the development, marketing, and manufacturing of complex pharmaceutical products. Under their leadership, the company has successfully registered over 600 products globally. Emerging market-approved manufacturing facilities: Business at Kwality is supported by state-of-art manufacturing facilities approved by many emerging markets. These facilities are fully capable of manufacturing complex injectables on a commercial scale Presence in over 60 countries through successful registrations: Kwality has successfully filed 600 products in different therapies and across dosages with strong presence in injectables. Injectable sales contributes ~70% to the overall company sales. Superior financials: Kwality revenues for FY22 increased by 74% to Rs 456.2 cr from Rs 262 cr while EBITDA grew to Rs 175.2 cr from Rs 30.4 cr compared with the year ago period. EBITDA margin stood at 38.4%. Net profit too increased to Rs 120 cr from Rs 15 cr compared with the same period a year ago. 7

View entire presentation